Factory snag hits GSK supply, causing
Danish anaesthetic shortage
Send a link to a friend
[June 17, 2016]
LONDON (Reuters) - Manufacturing problems at a factory in Italy
have disrupted production of some GlaxoSmithKline medicines, leading to
shortages of a commonly used opioid anaesthetic in Denmark.
The British drugmaker said on Friday it had temporarily suspended
manufacturing at its Parma site, which makes sterile products, to
investigate environmental monitoring, adding this was unrelated to
risks from any medicines.
The factory has now recommenced manufacturing. However, a
spokeswoman said a small number of countries had experienced
shortages of certain products since April.
In Denmark, doctors said they were running out of the anaesthetic
Ultiva, which is a preferred product because patients wake up
quickly after surgery. Recovery typically occurs within five to 10
The Parma factory also makes GSK's new injectable drug Nucala for
severe asthma and Benlysta for lupus, but the spokeswoman said these
medicines were not in short supply because there were plentiful
(Reporting by Ben Hirschler; Editing by Alexander Smith)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.